Applied Materials has snapped back sharply from last week's 10% selloff, and the Street wasted no time in raising its conviction on the recovery.
The rebound is real. The stock closed Tuesday at $499.21, up nearly 2% on the week and now sitting just 2% below the $510 level where it traded before the June 5 flush. The one-month return has climbed back to 14.6% despite last week's volatility. Within the peer group, the recovery has been uneven: KLAC is up 4.6% on the week and PDFS gained nearly 6%, while LRCX is still down 2.2% and MKSI is off 3.1%. AMAT's recovery is tracking the stronger half of the cohort, not the weaker.
The analyst community has responded to the dip with upgrades in conviction, not caution. UBS raised its target to $570 from $515 this morning, maintaining its Buy rating. Cantor Fitzgerald went further, lifting to $650 from $575, also today. Those follow a cluster of post-earnings target raises from BofA, Citigroup, and Deutsche Bank in mid-May, all reiterating Buy with targets in the $540–$550 range. The one dissenting voice remains Morgan Stanley, which downgraded to Equal-Weight on May 18 with a $502 target — essentially flat to current levels. The mean target of $517 implies only modest upside from here on consensus math alone, but the direction of travel from the more bullish shops is clearly higher. Factor scores support the bull case: the analyst recommendation differential ranks in the 98th percentile of the universe, and EPS momentum over the trailing 30 days ranks in the 83rd. The bear case centres on gross margin pressure and customer concentration — TSMC, Intel, and Samsung collectively drive a large share of revenue, and any capex pullback from that trio would hit AMAT disproportionately.
Short interest is not the story here, but it is worth watching. Shorts have added nearly 45% to their position over the past month, taking SI from roughly 13.9 million shares to 20.1 million — now at 2.5% of the free float. That's still a low absolute level, and the lending market reflects it: availability is essentially unlimited, with hundreds of millions of shares available to borrow and borrowing costs running at just 0.52%. There is no squeeze dynamic in play. The short build looks more like hedging into a volatile tape than a directional conviction bet against the name. Options positioning is similarly calm — the put/call ratio of 1.00 is marginally above its 20-day average of 0.99, with a z-score of just 0.73, well within normal range.
The insider picture is the one element that hasn't changed since last week's note. President Prabu Raja sold more than $25 million of stock on June 4, with CFO Brice Hill adding a $1.25 million sale on June 3. Both transactions came at prices above $498, suggesting insiders were comfortable selling into the post-earnings strength. The net 90-day insider selling figure is over $27 million. These are likely plan-driven sales, but the timing and size keep the question alive: insiders have shown no appetite to hold at these levels.
Next quarter's earnings are pencilled in for August 13. Between now and then, the debate is less about whether AMAT is executing — the May quarter removed most doubts on that front — and more about whether the Street's freshly raised targets can hold as the cycle matures and the Morgan Stanley caution proves early or prescient.
See the live data behind this article on ORTEX.
Open AMAT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
